

Gavi's potential role in pandemic preparedness and response

BOARD MEETING

David Kinder & Sanne Wendes

22-23 June 2022, Geneva, Switzerland



Reach every child

www.gavi.org

Gavi Alliance: an end-to-end approach, delivering PPR through core functions, leaving no one behind

	Gavi's 20 Years of innovation to fight outbreaks			What Gavi achieved	How Gavi's capacity helped drive the COVID-19 response	Gavi's priorities for an expanded contribution to PPR
Building Capacity for Preparedness	Meningitis stockpile	Cholera & Ebola stockpile	MenA: 332 m reached	70% Gavi investments support outbreak prevention, 521 vaccine introductions and campaigns. >888 m children vaccinated	Gavi leveraged the Alliance model to act as the engine for COVAX, delivering 1.3 bn AMC doses to date	An end-to-end vaccine partnership which delivers PPR through its core functions, putting countries at the centre <ul style="list-style-type: none"> • Innovates at pace • Agile, networked response • Equity at core
Financial Innovation for Response	First IFFIm bond	Rapid IFFIm Ebola commitment	Matching Fund Established	US\$ 4.5 bn transferred to Gavi from IFFIm, accelerating vaccine uptake to fight outbreaks	IFFIm mobilised US\$ 1.1 bn for an equitable response (COVAX) + 272 m for R&D (CEPI) New facilities to expedite global response: <ul style="list-style-type: none"> • 13 bn COVAX AMC / Pandemic Vaccine Pool • EIB liquidity facility • DFC Rapid Financing • MedAccess Risk Sharing 	Innovations retained and strengthened The Pandemic Vaccine Pool, and contingent financing via IFFIm to form part of the global PPR architecture Gavi seeking to become FIF implementing Partner
Market Shaping for Resilience	Ebola APC	Rapid support to RTS,S Malaria Vx production	From 5 to 18 suppliers 2000-2020	24% price reduction for pentavalent, pneumococcal and rotavirus vaccines: increasing efficiency and improving equity	World's largest, most diversified COVID vaccine portfolio, offering: <ul style="list-style-type: none"> • Supplier and geographical diversity • Risk sharing with manufacturers • Focus on affordability • Product choice for countries 	Shared vision for African Manufacturing <ul style="list-style-type: none"> • Potential new market shaping strategy • Working alongside AU and partners • Protect market-health and supply resilience

2000

2021

2022 – onward


Board meeting
22-23 June 2022



Gavi's programmatic and financial tools should be mainstreamed into the international processes underway to reform the global health PPR architecture

Global processes

- Pandemic Instrument (WHO)
- G7 Health and Development
- G20 Health and Finance-Health
- Financial Intermediary Fund



Gavi's role

~70% projected 5.0 expenditures support PPR

Building Capacity for Preparedness

- PPR considerations and innovations incorporated into Gavi 5.1

Financial Innovation for Response

- Request Gavi (+GF, CEPI) to be implementing partners to the FIF
- Sustain & develop Gavi's financial innovations e.g. PVP, IFFIm

Market Shaping for Resilience

- Proactive support to manufacturing diversification in Africa, including potential financing instrument

Gavi's experience in market-shaping for vaccines should be deployed to improve supply resilience, particularly in Africa



Gavi has a track record of supporting manufacturing diversification

- 5 Suppliers in **2000**, all in Europe/US
- Of 18 Suppliers in **2020**, 4 suppliers in Europe or North America



Gavi can use existing tools and approaches to support the agenda

- Input into product portfolio decisions
- “Self-procurement” under Gavi support
- Accommodation of a range of prices
- Commercial de-risk mechanism (APA, AMC)




Gavi going forward:

- Proactive stance
- Work with partners to set out a shared vision for growth of the sector in Africa



Resulting in:

- Options to support sustainable business models
- Possible financial instrument
- Increased diversity & resilience across multiple product profiles




● started ● planned ● discussions

ALGERIA	NIGERIA*
BOTSWANA	RWANDA
EGYPT*	SENEGAL*
GHANA	SOUTH AFRICA*
KENYA*	TUNISIA*
MOROCCO	TANZANIA
	UGANDA

**mRNA Tech Transfer Hub*

Development timeline - African vaccine manufacturing



Actions requested of the Board (1/2)

The Gavi Alliance Board is requested to **provide guidance** on the following three specific actions the Secretariat proposes to take over the next six months which are aimed at helping Gavi influence international processes and develop concrete new initiatives in support of the PPR agenda. Updates will be provided to the December 2022 Board meeting. The Secretariat will:

1. Ensure the benefits of the provision of epidemic and pandemic vaccines as a tool to strengthen PPR are embedded in the discussions at the WHO, G20 and G7 and that the resulting architecture reflects and enables Gavi's unique contribution to PPR, and reflects learning from the COVID-19 response.
2. Ensure the considerations outlined in this paper, including in relation to PPR-related financing instruments and support to the manufacturing agenda, will, where appropriate, be incorporated into the consideration of Gavi 5.1, pending Board approval in December, including any financial considerations (as per Doc 03).

Actions requested of the Board (2/2)

3. Working proactively with partners, including the African Union and Partnership for African Vaccine Manufacturing (PAVM), to set out a clear position on how Gavi can support sustainable regional manufacturing: providing an assessment of demand in the global vaccine market that could be filled by African manufacturers, and then developing options for pull-financing through new instruments, while considering the implications for the Gavi operating model. The Secretariat will provide the Board with an update on Gavi's support to this agenda in December 2022 as part of Gavi 5.1, reflecting inputs into the G7 (as requested by G7 Health and Development Ministers in May 2022) and ongoing engagement with AU and other partners.

THANK YOU



Reach every child
www.gavi.org